Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung Bioepis’ Biosimilar to Enbrel Wins EU Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Samsung Bioepis’ Biosimilar to Enbrel Wins EU Approval

Biogen will lead commercialization and distribution across all 28 EU member states, Norway, Iceland and Liechtenstein

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Bioepis Co. received approval from the European Commission for Benepali, a biosimilar to Amgen’s Enbrel (etanercept), for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis.

In a 52-week Phase III study, Benepali demonstrated comparable safety and equivalent efficacy to Enbrel, with a ACR20 response rate of 80.8% in the Benepali arm versus 81.5% in the Enbrel arm.

Benepali will be marketed across all 28 European Union (EU) member states as well as the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Under a commercialization agreement signed in 2013, Biogen will lead the commercialization and distribution of Benepali in the EU and EEA member states.

“The approval of Benepali and its subsequent launches in Europe are major milestones for Samsung Bioepis,” said Christopher Hansung Ko, president and chief executive officer of Samsung Bioepis. “In just under four years, we successfully developed, tested and obtained regulatory approval for Benepali, a high-quality biologic medicine that will drive down healthcare costs and increase patient access to one of the most widely used treatment options for immunological diseases across Europe.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics